SCHEMBL20768152

SCHEMBL20768152

CN1CCN(c2ccc3[nH]c(-c4ccc5[nH]c(-c6ccccc6)nc5c4)nc3c2)CC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.63
SMN1; SMN2 Q16637 4/20 0.63
TOP1 P11387 3/20 0.63
TOP2A P11388 3/20 0.63
HPGD P15428 1/20 0.63
HSD17B10 Q99714 1/20 0.63
KDM4E B2RXH2 3/20 0.59
NPC1 O15118 1/20 0.59
POLB P06746 1/20 0.59
RAB9A P51151 1/20 0.59
MAPT P10636 3/20 0.57
MEN1 O00255 2/20 0.57
BLM P54132 2/20 0.57
KMT2A Q03164 2/20 0.57
SLCO2B1 O94956 1/20 0.57
GLA P06280 1/20 0.57
RECQL P46063 1/20 0.57
BCL2L1 Q07817 1/20 0.57
SLCO1B3 Q9NPD5 1/20 0.57
TDP1 Q9NUW8 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8769012 0.94 ALDH1A1 (0.72) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL14665474 0.91 SMN1; SMN2 (0.66) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL19484925 0.90 ALDH1A1 (0.63) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL6530109 0.90 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL340370 0.89 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
Hoechst 33258 SCHEMBL29350619 0.89 ALDH1A1 (0.79) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
Hoechst 33258 SCHEMBL617906 0.89 ALDH1A1 (0.79) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL3171446 0.89 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL21017604 0.89 DGAT1 (0.63) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
Hoechst 33258 SCHEMBL21847754 0.88 ALDH1A1 (0.77) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11213546-B2 Methods to mobilize tissue resident cells for adoptive t cell therapy EMORY UNIVERSITY (US) 2022-01-04 US disclosed
US-20190070221-A1 Methods to Mobilize Tissue Resident Cells for Adoptive T Cell Therapy EMORY UNIVERSITY 2019-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190070221-A1 Methods to Mobilize Tissue Resident Cells for Adoptive T Cell Therapy CD69, CD47, ICOS ALDH1A1 3002/4885SMN1; SMN2 1343/4885TOP1 2213/4885
US-11213546-B2 Methods to mobilize tissue resident cells for adoptive t cell therapy CD69, CD47, ICOS ALDH1A1 3002/4885SMN1; SMN2 1343/4885TOP1 2213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.